New data shows Cladribine reduces brain atrophy in patients with MS

Newly released data published in the Multiple Sclerosis Journal shows Cladribine tablets significantly reduce brain atrophy in patients suffering with multiple sclerosis (MS).
The data was gathered on an EDSS scale, a measure that quantifies disabilities in patients with MS. The results were published by Merck, a leading science and technology company.
“Evidence shows that brain atrophy in general accumulates throughout the course of multiple sclerosis and is associated with disability progression,” Nicola de Stefano, lead author of the publication and associate professor of neurology at the University of Siena, said in a news release. “This analysis is important because it confirms the link between reduced brain atrophy and reduced disability progression found in the study.”
MS is an inflammatory condition that debilitates the central nervous system. Most common symptoms include blurred vision, numbness or tingling in the limbs, and problems with strength and coordination.
“These findings reinforce and expand on the consistent and positive effect of Cladribine in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with [relapsing remitting multiple sclerosis],” Steven Hildermann, global chief medical officer and head of global medical affairs and safety of Merck, said.